Insider Transactions in Q4 2025 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
12,128
-3.76%
|
$5,530,368
$456.7 P/Share
|
|
Nov 17
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
8,161
+19.64%
|
$971,159
$119.13 P/Share
|
|
Nov 13
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.56%
|
$4,510,000
$451.86 P/Share
|
|
Nov 13
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.71%
|
$1,190,000
$119.13 P/Share
|
|
Nov 12
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,650
-1.92%
|
$7,089,450
$453.42 P/Share
|
|
Nov 12
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,650
+8.29%
|
$1,252,000
$80.67 P/Share
|
|
Oct 03
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
3,022
-2.74%
|
$1,365,944
$452.05 P/Share
|
|
Oct 02
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,821
-0.57%
|
$1,727,092
$452.32 P/Share
|
|
Oct 02
2025
|
Pushkal Garg EVP Chief R&D |
SELL
Open market or private sale
|
Direct |
2,937
-0.98%
|
$1,327,524
$452.32 P/Share
|
|
Oct 02
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
2,441
-0.76%
|
$1,103,332
$452.32 P/Share
|
|
Oct 02
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,405
-0.41%
|
$635,060
$452.32 P/Share
|
|
Oct 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,924
-1.06%
|
$4,033,648
$452.32 P/Share
|
|
Oct 01
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,752
+6.47%
|
-
|
|
Oct 01
2025
|
Bryan Supran EVP, CLO and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
13,026
+50.0%
|
-
|
|
Oct 01
2025
|
Pushkal Garg EVP Chief R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,959
+10.79%
|
-
|
|
Oct 01
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
4,953
+8.57%
|
-
|
|
Oct 01
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,851
+9.0%
|
-
|
|
Oct 01
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,112
+11.06%
|
-
|